Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study

Linong Ji,1 Kyung Wan Min,2 Juliana Oliveira,3 Thomas Lew,4 Ran Duan3 1Department of Endocrinology, Peking University People's Hospital, Beijing, People's Republic of China; 2Department of Endocrinology, Eulji Hospital, Seoul, Republic of Korea; 3Eli Lilly and Company, Indianapolis,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ji L, Min KW, Oliveira J, Lew T, Duan R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Ethnicity Insulin Race Type 2 Diabetes Mellitus Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c6a32134e4824cf197dae53674b847fb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6a32134e4824cf197dae53674b847fb
record_format	dspace
spelling	oai:doaj.org-article:c6a32134e4824cf197dae53674b847fb2021-12-02T00:16:03ZComparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study1178-7007https://doaj.org/article/c6a32134e4824cf197dae53674b847fb2016-08-01T00:00:00Zhttps://www.dovepress.com/comparison-of-efficacy-and-safety-of-two-starting-insulin-regimens-in--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Linong Ji,1 Kyung Wan Min,2 Juliana Oliveira,3 Thomas Lew,4 Ran Duan3 1Department of Endocrinology, Peking University People's Hospital, Beijing, People's Republic of China; 2Department of Endocrinology, Eulji Hospital, Seoul, Republic of Korea; 3Eli Lilly and Company, Indianapolis, IN, USA; 4Eli Lilly and Company, Taipei, Songshan District, Taiwan Objective: The objective of this study was to explore the efficacy and safety of insulin lispro mix 25 (25% insulin lispro and 75% insulin lispro protamine suspension [LM25]) or insulin glargine plus insulin lispro (G+L) in insulin-naïve patients with type 2 diabetes from different racial/ethnic groups. Methods: Three subgroups from the PARADIGM study were analyzed post hoc: non-Asian (n=130), Asian Indian (n=106), and East Asian (n=89). Results: All subgroups recorded glycated hemoglobin (HbA1c) reductions: non-Asian (LM25, -2.07%; G+L, -2.05%), Asian Indian (LM25, -1.75%; G+L, -1.60%), and East Asian (LM25, -2.03%; G+L, -1.76%); end point HbA1c values were higher in Asian Indians and East Asians than in non-Asians. Fewer Asian Indians (LM25, 43.2%; G+L, 29.2%) and East Asians (LM25, 37.5%; G+L, 36.1%) reached HbA1c ,7% versus non-Asians (LM25, 51.7%; G+L, 48.1%); differences were not significant (P=0.12 and P=0.06, respectively). The mean total daily insulin dose (U/kg) for non-Asians was 0.67 (LM25) and 0.61 (G+L), for Asian Indians was 0.91 (LM25) and 0.90 (G+L), and for East Asians was 0.53 (LM25) and 0.59 (G+L). The ratio of mealtime to total insulin dose in the G+L arm for non-Asians was 0.19±0.23, for Asian Indians was 0.33±0.25, and for East Asians was 0.34±0.27. Overall incidence (%) of hypoglycemia in non-Asians was 94.1 (LM25) and 91.8 (G+L), in Asian Indians was 90.4 (LM25) and 88.5 (G+L), and in East Asians was 69.8 (LM25) and 77.3 (G+L). Conclusion: Asian Indians showed least improvement in glycemic HbA1c reduction despite greater insulin use. East Asians and non-Asians achieved similar HbA1c reduction in the LM25 arm with a lower rate of hypoglycemia. Asians required more mealtime insulin coverage than non-Asians. This study added important insight into the effect of ethnicity on insulin treatment outcomes in patients with type 2 diabetes. Keywords: ethnicity, insulin, race, type 2 diabetes mellitusJi LMin KWOliveira JLew TDuan RDove Medical PressarticleEthnicityInsulinRaceType 2 Diabetes MellitusSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 243-249 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ethnicity Insulin Race Type 2 Diabetes Mellitus Specialties of internal medicine RC581-951
spellingShingle	Ethnicity Insulin Race Type 2 Diabetes Mellitus Specialties of internal medicine RC581-951 Ji L Min KW Oliveira J Lew T Duan R Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study
description	Linong Ji,1 Kyung Wan Min,2 Juliana Oliveira,3 Thomas Lew,4 Ran Duan3 1Department of Endocrinology, Peking University People's Hospital, Beijing, People's Republic of China; 2Department of Endocrinology, Eulji Hospital, Seoul, Republic of Korea; 3Eli Lilly and Company, Indianapolis, IN, USA; 4Eli Lilly and Company, Taipei, Songshan District, Taiwan Objective: The objective of this study was to explore the efficacy and safety of insulin lispro mix 25 (25% insulin lispro and 75% insulin lispro protamine suspension [LM25]) or insulin glargine plus insulin lispro (G+L) in insulin-naïve patients with type 2 diabetes from different racial/ethnic groups. Methods: Three subgroups from the PARADIGM study were analyzed post hoc: non-Asian (n=130), Asian Indian (n=106), and East Asian (n=89). Results: All subgroups recorded glycated hemoglobin (HbA1c) reductions: non-Asian (LM25, -2.07%; G+L, -2.05%), Asian Indian (LM25, -1.75%; G+L, -1.60%), and East Asian (LM25, -2.03%; G+L, -1.76%); end point HbA1c values were higher in Asian Indians and East Asians than in non-Asians. Fewer Asian Indians (LM25, 43.2%; G+L, 29.2%) and East Asians (LM25, 37.5%; G+L, 36.1%) reached HbA1c ,7% versus non-Asians (LM25, 51.7%; G+L, 48.1%); differences were not significant (P=0.12 and P=0.06, respectively). The mean total daily insulin dose (U/kg) for non-Asians was 0.67 (LM25) and 0.61 (G+L), for Asian Indians was 0.91 (LM25) and 0.90 (G+L), and for East Asians was 0.53 (LM25) and 0.59 (G+L). The ratio of mealtime to total insulin dose in the G+L arm for non-Asians was 0.19±0.23, for Asian Indians was 0.33±0.25, and for East Asians was 0.34±0.27. Overall incidence (%) of hypoglycemia in non-Asians was 94.1 (LM25) and 91.8 (G+L), in Asian Indians was 90.4 (LM25) and 88.5 (G+L), and in East Asians was 69.8 (LM25) and 77.3 (G+L). Conclusion: Asian Indians showed least improvement in glycemic HbA1c reduction despite greater insulin use. East Asians and non-Asians achieved similar HbA1c reduction in the LM25 arm with a lower rate of hypoglycemia. Asians required more mealtime insulin coverage than non-Asians. This study added important insight into the effect of ethnicity on insulin treatment outcomes in patients with type 2 diabetes. Keywords: ethnicity, insulin, race, type 2 diabetes mellitus
format	article
author	Ji L Min KW Oliveira J Lew T Duan R
author_facet	Ji L Min KW Oliveira J Lew T Duan R
author_sort	Ji L
title	Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study
title_short	Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study
title_full	Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study
title_fullStr	Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study
title_full_unstemmed	Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study
title_sort	comparison of efficacy and safety of two starting insulin regimens in non-asian, asian indian, and east asian patients with type 2 diabetes: a post hoc analysis of the paradigm study
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/c6a32134e4824cf197dae53674b847fb
work_keys_str_mv	AT jil comparisonofefficacyandsafetyoftwostartinginsulinregimensinnonasianasianindianandeastasianpatientswithtype2diabetesaposthocanalysisoftheparadigmstudy AT minkw comparisonofefficacyandsafetyoftwostartinginsulinregimensinnonasianasianindianandeastasianpatientswithtype2diabetesaposthocanalysisoftheparadigmstudy AT oliveiraj comparisonofefficacyandsafetyoftwostartinginsulinregimensinnonasianasianindianandeastasianpatientswithtype2diabetesaposthocanalysisoftheparadigmstudy AT lewt comparisonofefficacyandsafetyoftwostartinginsulinregimensinnonasianasianindianandeastasianpatientswithtype2diabetesaposthocanalysisoftheparadigmstudy AT duanr comparisonofefficacyandsafetyoftwostartinginsulinregimensinnonasianasianindianandeastasianpatientswithtype2diabetesaposthocanalysisoftheparadigmstudy
_version_	1718403889916542976

Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study

Ejemplares similares